Relationship between treatment resistance to hemoperfusion using a polymyxin b-immobilized fiber column and oxidative stress

ASAIO Journal

Volumn 54, Issue 4, 2008, Pages 412-415

  Sakamoto, Yuichiro ^a   Mashiko, Kunihiro ^a   Obata, Toru ^b   Matsumoto, Hisashi ^a   Hara, Yoshiaki ^a   Kutsukata, Noriyoshi ^a   Yamamoto, Yasuhiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2-GROUP; ACUTE LUNG INJURY; ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATIONS; ACUTE RESPIRATORY DISTRESS SYNDROME; HEMOPERFUSION; ISOPROSTANE; LUNG INJURY; ORGAN FAILURE; OXIDATIVE STRESS MARKERS; POLYMYXIN B; RESPIRATORY DISEASE; SEPTIC SHOCKS; SERUM LEVELS;

BIOLOGICAL ORGANS; OXYGENATION; OXYGENATORS;

PULMONARY DISEASES;

ISOPROSTANE DERIVATIVE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICE THERAPY; DISEASE RESISTANCE; FEMALE; HEMOPERFUSION; HUMAN; LUNG INJURY; MALE; OXIDATIVE STRESS; OXYGEN TENSION; OXYGENATION; POLYMYXIN B IMMOBILIZED FIBER COLUMN THERAPY; SEPTIC SHOCK; BLOOD; DRUG RESISTANCE; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE; F2-ISOPROSTANES; FEMALE; HEMOPERFUSION; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMYXIN B; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC;

EID: 51149084167     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31817e511b     Document Type: Article

References (23)

1. Janssen LJ, Catalli A, Helli P: The pulmonary biology of isopros-tanes. Antioxid Redox Signal 7: 244-255, 2005.
2. Gattinoni L, Pelosi P, Suter P, et al: Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease : Different syndrome? Am J Respir Crit Care Med 158: 3-11, 1998.
3. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000.
4. Seo Y, Abe S, Kurahara M, et al: Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 45: 1033-1038, 2006.
5. Kushi H, Miki T, Okamoto K, et al: Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9: R653-R661, 2005.
6. Sato T, Shoji H, Koga N: Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflamma tory response syndrome: The Japan experience. Ther Apher Dial 7: 252-258, 2003.
7. Cruz DN, Perazella MA, Bellomo R, et al: Effectiveness of poly-myxin B-immobilized fiber column in sepsis: A systematic review. Crit Care 11: R47, 2007.
8. Tani T, Hanasawa K, Kodama M, et al: Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 in septic patients. World J Surg 25: 660-668, 2001.
9. Sakamoto Y, Mashiko K, Matsumoto H, et al: Relationship between effect of polymyxin B-immobilized fiber and high mobility group box-1 protein in septic shock patients. ASAIO J 53: 324-328, 2007.
10. Sakamoto Y, Mashiko K, Matsumoto H, et al: Effect of direct hemoperfusion with a polymyxin B immobilized fiber column on high mobility group box-1 (HMGB-1) in severe septic shock: Report of a case. ASAIO J 52: 37-39, 2006.
11. Sakamoto Y, Mashiko K, Obata T, et al: Clinical responses and improvement of some laboratory parameters following poly-myxin B-immobilized fiber treatment in septic shock. ASAIO J 53: 646-650, 2007.
12. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure: On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Int Care Med 22: 707-710, 1996.
13. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167: 412-417, 1994.
14. Vincent JL, Laterre PF, Cohen J, et al: A Pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23: 400-405, 2005.
15. Gutteridge JM, Mitchell J: Redox imbalance in the critically ill. Br Med Bull 55: 49-75, 1999.
16. Otani K, Shimizu S, ChijiiwaK, et al: Increased urinary excretion of bilirubin oxidative metabolites in septic patients: A new marker for oxidative stress in vivo. J Surg Res 96: 44-49, 2001.
17. Roberts LJ, Morrow JD: Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28: 505-513, 2000.
18. Milne GL, Musiek ES, Morrow JD: F2-isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers 10: S10-S23, 2005.
19. Janssen LJ: Isoprostane: An overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 280: L1067-L1082, 2001.
20. Carpenter CT, Price PV, Christian BW: Exhaled breath isopros-tanes are elevated in patients with lung injury and ARDS. Chest 114: 1653-1659, 1998.
21. Roberts LJ II, Oates JA, Linton MF, et al: The relationship between dose of vitamine E and suppression of oxidative stress in humans. Free Radic Biol Med 43: 1388-1393, 2007.
22. Carlson D, Maass DL, White DJ, et al: Antioxidant vitamin therapy alters sepsis-related apoptotic myocardial activity and inflammatory responses. Am J Physiol Heart Circ Physiol 291: H2779-H2789, 2006.
23. Sakamoto Y, Mashiko K, Obata T, et al: Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 54: 129-132, 2008.